XENICAL remains a well-recognized option for obesity management, offering clinically significant weight loss and metabolic benefits through a unique fat-blocking mechanism. However, its high ...

Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Company (PG), Novo ...

Equity markets may be struggling because of President Donald Trump's current economic policies, but that doesn't mean ...

Historical trends and future projections of the number of people with overweight and obesity suggest alarming parallel ...

Bagsværd: Novo Nordisk HA has announced that Camilla Sylvest has decided to leave the company after a distinguished career of ...

Denmark’s benchmark stock index has fallen 21% from its September high, making it the first major European index to enter a bear market as tariff-related risks and a slump for Novo Nordisk A/S weigh.

Novo Holdings, the controlling shareholder of weight loss drugmaker Novo Nordisk A/S (NYSE:NVO), reported Wednesday income and investment returns of 60 billion Danish kroner (around $8.68 billion) for ...

Artisan Partners, an investment management company, released its “Artisan Global Opportunities Fund” fourth quarter 2024 ...

Novo Nordisk shares have dropped ~50% since June 2024 due to poor trial results and other negative catalysts. See why I rate ...

Vaccine makers were hit particularly hard yesterday, as Marks’ resignation letter alluded to disagreements with HHS Secretary ...

A series of disappointing trial results for Novo Nordisk’s next-generation weight-loss drugs has exacerbated investor concerns about its competitiveness. In December 2024, the company announced phase ...